Clinical Trial Update: Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating GAP-486 on heart rhythm in patients with coronary artery disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmia
• Coronary Artery Disease

Drugs mentioned

• GAP-486

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Arrhythmia | Phase 2 | Status: TERMINATED